Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

por Ludwig, Heinz, Greil, Richard, Masszi, Tamas, Spicka, Ivan, Shpilberg, Ofer, Hajek, Roman, Dmoszynska, Anna, Paiva, Bruno, Vidriales, María‐Belén, Esteves, Graca, Stoppa, Anne Marie, Robinson, Don, Chaturvedi, Shalini, Ataman, Ozlem, Enny, Christopher, Feng, Huaibao, van de Velde, Helgi, Viterbo, Luisa
Publicado 2015

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE(2)-receptor E-type 4 (EP4), in patients with advanced cancers

por Hong, David S, Parikh, Aparna, Shapiro, Geoffrey I, Varga, Andrea, Naing, Aung, Meric-Bernstam, Funda, Ataman, Özlem, Reyderman, Larisa, Binder, Terri A, Ren, Min, Liu, Mingjie, Dayal, Satish, Siu, Amy Y, Sachdev, Pallavi, Xu, Lucy, Bhagawati-Prasad, Vijay, Tchakov, Ilian, Ooi, Chean Eng, Bao, Xingfeng, Marabelle, Aurelien
Publicado 2020